Digoxin was approved by the Food and Drug Administration in 1954 and its inhibitory effect on AV conduction is used for ventricular rate control in AF and atrial flutter (Whayne, 2018). In current guidelines, digoxin is used for rate control in AF or atrial flutter when Class II or Class ...
Administer by slow (over at least 5 minutes) IV infusion; avoid rapid (i.e., bolus) IV administration since systemic and coronary vasoconstriction may occur.DosageDosage guidelines provided are based upon average patient response; substantial patient variation can be expected.Dosage may be initiated...
Avoid rapid IV administration in digitalized patients; may produce serious arrhythmias. Not necessary to routinely reduce or hold digoxin therapy prior toelectiveelectrical cardioversion for atrial fibrillation; however, exclusion of digoxin toxicity is necessary prior to cardioversion; withhold digoxin and d...
For the quantification of viral copy number, total RNA was isolated from cell supernatants using the QIAamp viral RNA mini kit (Qiagen, Hilden, Germany) and cDNA was synthesized from 1 μg of total RNA using SuperScript IV (Invitrogen, Waltham, MA, USA) according to the manufacturer’s prot...